Moody National Bank Trust Division Makes New $544,000 Investment in Novo Nordisk A/S $NVO

Moody National Bank Trust Division purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,352 shares of the company’s stock, valued at approximately $544,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capital Investment Counsel LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $3,727,000. Marathon Capital Management grew its position in Novo Nordisk A/S by 43.9% during the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock worth $4,208,000 after purchasing an additional 25,230 shares during the last quarter. Burney Co. purchased a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $1,374,000. Burkett Asset Management Ltd acquired a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $1,823,000. Finally, Tevis Investment Management increased its stake in Novo Nordisk A/S by 65.7% during the 1st quarter. Tevis Investment Management now owns 74,090 shares of the company’s stock valued at $2,813,000 after purchasing an additional 29,390 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 3.1%

Shares of NVO stock opened at $45.90 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The stock has a market cap of $204.96 billion, a P/E ratio of 11.22, a P/E/G ratio of 4.06 and a beta of 0.76. The stock has a 50 day moving average of $46.96 and a 200 day moving average of $45.01. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be issued a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio is 42.79%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strong quarterly results and raised outlook: Novo Nordisk beat second-quarter revenue expectations by approximately 10% and adjusted EPS estimates by more than 20%. Revenue increased 7% year over year, operating profit rose 11%, and management lifted its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
• Positive Sentiment: Continued GLP-1 demand: International markets and obesity care continued to drive growth, while accelerating demand for the Wegovy pill supported the improved outlook. The company also retains substantial profitability and cash generation to fund research, development and shareholder returns. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: Patent enforcement win: A Dutch court ordered Ceban Ziekenhuisfarmacie to stop selling an infringing compounded semaglutide nasal spray, remove product listings and provide supply-chain information. The ruling could help protect Novo’s semaglutide franchise from unauthorized competition in the Netherlands. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: Novo declared a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the stated dividend and should be treated cautiously pending confirmation. Novo Nordisk dividend and insider transactions announcement
• Negative Sentiment: Pipeline and competitive concerns remain the main overhang: Investors focused on weaker-than-expected Wegovy pill sales, a setback for the next-generation obesity treatment CagriSema, U.S. pricing pressure and the widening commercial lead of Eli Lilly’s GLP-1 portfolio. These issues overshadowed the earnings beat and guidance increase. The divide between Eli Lilly and Novo Nordisk is widening

Analysts Set New Price Targets

Several research firms have recently commented on NVO. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. BMO Capital Markets restated a “market perform” rating and issued a $47.00 target price on shares of Novo Nordisk A/S in a research note on Thursday. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Five analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.81.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.